Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a23dcd2e7b574603

Jump to content

Substance Access Beneficiary Engagement Incentive

From Wikipedia, the free encyclopedia

Substance Access Beneficiary Engagement Incentive is a US government Centers for Medicare & Medicaid Services (CMS) policy that took effect on April 1, 2026. The policy allows Medicare and Medicaid covered individuals to receive $500 worth of hemp-derived CBD and THC products annually for medical purposes.[1] At inception, providers were required to be enrolled in ACO REACH program (Accountable Care Organization Realizing Equity, Access, and Community Health) or Enhancing Oncology Model, with later expansion to LEAD (Long-term Enhanced ACO Design) planned.[2] Covered products may have up to 0.3% delta-9 THC.[3]

A federal lawsuit and request for temporary restraining order to prevent implementation on April 1, 2006 was filed by prohibitionist group Smart Approaches to Marijuana. A judge refused to issue a restraining order, allowing the program to go into effect, and scheduled a hearing for April 20, 2026.[4]

On April 2, 2026, the commissioner of the United States Food and Drug Administration (FDA) wrote a letter to subordinates directing exemptions to drug labeling and other regulatory requirements to avoid interference with the CMS program.[5]

References

[edit]
  1. Molly Parks (March 31, 2026). "What to know about Medicare's new hemp pilot program that drug safety groups are challenging in court". Washington Examiner.(subscription required)
  2. Mackenzie Bean, "CMS pilot allows hemp products in care plans: 5 notes", Becker's Hospital Review
  3. "Substance Access Beneficiary Engagement Incentive overview". Official website. Centers for Medicare & Medicaid Services.
  4. Tony Lange (April 1, 2026). "Judge Denies SAM's Temporary Restraining Order; CBD Pilot Program Launches". Cannabis Business Times.
  5. Tony Lange (April 2, 2026), "FDA Takes Hands-Off Approach to Medicare's CBD Product Program", Cannabis Business Times, The U.S. Food and Drug Administration commissioner clarified the agency's enforcement posture related to CBD product coverage under Medicare's new plan.
[edit]